The real-world efficacy and safety of direct-acting oral antiviral treatment in chronic Hepatitis C Genotype 1 patients in Turkey

Erol Çakmak

doi:10.7197/223.vi.376221

TR EN

Türkiye’de kronik Hepatit C Genotip 1 hastalarında direkt-etkili oral antiviral tedavinin gerçek yaşamda etkinliği ve güvenliği

Öz

Amaç: Bu çalışmanın amacı, Türkiye'de ve dünyada kronik hepatit C virüsünün (HCV) en yaygın şekli olan genotip 1 hastalarında kullanılan paritaprevir / ritonavir, ombitasvir, dasabuvir (PrOD) ± ribavirin (RBV) ve ledipasvir / sofosbuvir (LDV / SOF) ± RBV kombinasyon rejimlerinin gerçek yaşamda etkinliğini ve güvenirliğini araştırmakdı.

Yöntem: Haziran 2016 ile Ekim 2017 yılları arasında, PrOD ± RBV veya LDV / SOF ± RBV tedavi rejimleri alan toplam 81 HCV genotipi 1 hasta dahil edildi. Hastalar demografik, klinik ve virolojik verileri, kalıcı virolojik yanıt (KVY) ve ayrıntılı yan etkiler değerlendirildi.

Bulgular: 81 HCV hastası, 35 (% 43.2) erkek, 46 (% 56.8) kadın olup ortalama yaş 62 idi. Hastalar Türkiye'de en sık görülen genotip olan genotip 1 ve alt genotipler % 12.3 genotip 1a ve % 87.7 genotip 1b idi. Kronik HCV genotip 1 hastalarının KVY oranı 79 (% 96.4), PrOD ± RBV hastalarında % 98.2 ve SOF / LDV ± RBV'de % 96 idi. Ayrıntılı yan etki 46 (% 56.8) hastada bildirildi. Hastalarda en sık görülen yan etkiler; 18 (% 22.2) kaşıntı, 17 yorgunluk (% 21) ve 16 (% 19.8) baş ağrısı idi.

Sonuç: Bu çalışmada bölgemizdeki tek bir merkezden elde edilen gerçek yaşam verilerine göre, kronik HCV genotip 1 hastalarında direkt etkili oral viral tedavi rejimleri ile yüksek KVY 12 yanıtı elde edildi ve mükemmel tolere edildiği görüldü.

Anahtar Kelimeler

Antiviral ajanlar,Hepatitis C kronik,güvenlik,kalıcı viral yanıt,kalıcı viral yanıt

Kaynakça

1. Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am 2015; 44: 717-34.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: 45-57.
3. Tozun N, Ozdogan O, Cakaloglu, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21(11):1020-26.
4. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.
5. Gürbüz Y, Tülek NE, Tütüncü EE, et al. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study, Balkan Medikal J 2016; 33: 18-26.
6. Backus LI, Boothroyd DB, Philips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.
7. McHutchison JG, Lawitz EJ, Shiffman ML, et al. IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med, 2009; 361: 580-93.
8. Lawitz EJ, Membreno FE. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. J Gastroenterol Hepatol 2014; 29: 1574-8.

9. Ahmed H , Abushouk AI, Menshawya A, et al. Safety and Efficacy of Ombitasvir/ Paritaprevir/ Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig 2017; 37: 1009-23.
10. Flisiak R, Łucejko M, Mazur W, et al. Effectiveness and safety of ledipasvir /sofosbuvir ± ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci 2017; 62: 387-92.
11. Tao T, Jiang X, Chen Y, Song Y. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Int J Infect Dis 2017; 55: 56-71.
12. Gürbüz Y, Tülek NE, Tobacci EE, et al. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med. J, 2016; 33: 18-26.
13. Ferenci P, Bernstein D, Lalezari J, et al. PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med, 2014; 370: 1983-92.
14. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med, 2014; 370: 1973-82.
15. Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
16. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.N Engl J Med 2014; 370: 1483-93.
17. Welzel TM, Hinrichsen H, Sarrazin C, et al, Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 2017; 24: 840-49.
18. Chan HL, Tsang OT, Hui YT, et al. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. J Gastroenterol Hepatol 2017; 32: 1230-33.
19. Shin HP, Burman B, Kozarek RA, et al. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. Gut Liver 2017; 11: 711-20.
20. Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of ledipasvir/ sofosbuvir ± ribavirin vs. ombitasvir/ paritaprevir /ritonavir/dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther, 2016; 44: 400-10.
21. Calleja JL, Crespo J, Rincón D, et al. Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol 2017; 66: 1138-48.
22. Su F, Best LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol 2017; 29: 686-93.
23. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30-32.
24. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology 2016; 151: 501-12.
25. Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol 2012; 47: 1014-21.
26. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
27. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials Hepatology 2015; 62: 25-30.
28. Mendizabal M, Haddad L, Gallardo PE, et al. Ombitasvir/paritaprevir/ritonavir/ dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. J Med Virol, 2017; 89: 1590-96.
29. Terrault NA, Zeuzem S, Bisceglie D, et al. HCV-TARGET Study Group Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology 2016; 151: 1131-40.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Erol Çakmak
Türkiye

Yayımlanma Tarihi

20 Mart 2018

Gönderilme Tarihi

8 Ocak 2018

Kabul Tarihi

25 Şubat 2018

Yayımlandığı Sayı

Yıl 1970 Cilt: 40 Sayı: 1

DOI

https://doi.org/10.7197/223.vi.376221

IZ

https://izlik.org/JA39ES74FP

Kaynak Göster

RIS / Bibtex

AMA

1.Çakmak E. The real-world efficacy and safety of direct-acting oral antiviral treatment in chronic Hepatitis C Genotype 1 patients in Turkey. CMJ. 2018;40(1):56-64. doi:10.7197/223.vi.376221

Cited By

Kronik hepatit C tedavisinde ikinci kuşak direk etkili oral antivirallerin gerçek yaşam verileri: Tek merkez ve heterojen hasta grubu

Akademik Gastroenteroloji Dergisi

https://doi.org/10.17941/agd.843318

Evaluation of Direct-acting Antiviral Agents and Clinical Responses in Chronic Hepatitis C Patients

Viral Hepatitis Journal

https://doi.org/10.4274/vhd.galenos.2022.2022-4-2

Türkiye’de kronik Hepatit C Genotip 1 hastalarında direkt-etkili oral antiviral tedavinin gerçek yaşamda etkinliği ve güvenliği

Türkiye’de kronik Hepatit C Genotip 1 hastalarında direkt-etkili oral antiviral tedavinin gerçek yaşamda etkinliği ve güvenliği

Öz

Anahtar Kelimeler